Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 108

1.

Metabolic dysfunction in a rat model of early-life scarcity-adversity: Modulatory role of cafeteria diet.

Sagae SC, Zanardini B, Ribeiro-Paz ED, Amaral AC, Bronczek GA, Lubaczeuski C, Grassiolli S, Koehler-Santos P, de Oliveira JR, Donadio MVF, Raineki C.

Exp Physiol. 2018 Nov;103(11):1481-1493. doi: 10.1113/EP087171. Epub 2018 Oct 8.

PMID:
30211444
2.

Life-long Maternal Cafeteria Diet Promotes Tissue-Specific Morphological Changes in Male Offspring Adult Rats.

Santos CDS, Balbo SL, Guimarães ATB, Sagae SC, Negretti F, Grassiolli S.

An Acad Bras Cienc. 2017 Oct-Dec;89(4):2887-2900. doi: 10.1590/0001-3765201720170316.

3.

Nanoencapsulation of lutein and its effect on mice's declarative memory.

do Prado Silva JT, Geiss JMT, Oliveira SM, Brum EDS, Sagae SC, Becker D, Leimann FV, Ineu RP, Guerra GP, Gonçalves OH.

Mater Sci Eng C Mater Biol Appl. 2017 Jul 1;76:1005-1011. doi: 10.1016/j.msec.2017.03.212. Epub 2017 Mar 27.

PMID:
28482463
4.

Contributions of the Japanese Gynecologic Oncology Group (JGOG) in Improving the Quality of Life in Women With Gynecological Malignancies.

Futagami M, Yokoyama Y, Shimada M, Sato S, Miyagi E, Tozawa-Ono A, Suzuki N, Fujimura M, Aoki Y, Sagae S, Sugiyama T.

Curr Oncol Rep. 2017 Apr;19(4):25. doi: 10.1007/s11912-017-0580-y. Review.

PMID:
28303492
5.

Advances and Concepts in Cervical Cancer Trials: A Road Map for the Future.

Sagae S, Monk BJ, Pujade-Lauraine E, Gaffney DK, Narayan K, Ryu SY, McCormack M, Plante M, Casado A, Reuss A, Chávez-Blanco A, Kitchener H, Nam BH, Jhingran A, Temkin S, Mileshkin L, Berns E, Scholl S, Doll C, Abu-Rustum NR, Lecuru F, Small W Jr; Gynecologic Cancer InterGroup Cervix Cancer brainstorming day.

Int J Gynecol Cancer. 2016 Jan;26(1):199-207. doi: 10.1097/IGC.0000000000000587.

6.

[Blockade of AT1 receptor of Angiotensin II reduces the number of antral follicles in female rats with obesity induced by cafeteria diet].

Sagae SC, Gobo CG, Paz ED, Menegotto JB, Yamashita PK, Franci CR, Balbo SL.

Rev Bras Ginecol Obstet. 2015 Jul;37(7):302-7. doi: 10.1590/S0100-720320150005352. Portuguese.

7.

Gynecologic Cancer InterGroup (GCIG) consensus review for uterine serous carcinoma.

Sagae S, Susumu N, Viswanathan AN, Aoki D, Backes FJ, Provencher DM, Vaughan M, Creutzberg CL, Kurzeder C, Kristensen G, Lee C, Kurtz JE, Glasspool RM, Small W Jr.

Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S83-9. doi: 10.1097/IGC.0000000000000264. Review.

PMID:
25341586
8.

Prevention of metabolic disorders and reproductive performance deficits by the blockade of Angiotensin II AT1 receptor in female rats fed with cafeteria diet.

Sagae SC, Lubaczeuski C, Zacharias P, Bonfleur ML, Franci CR, Sanvitto GL.

Physiol Behav. 2013 Jul 2;119:1-8. doi: 10.1016/j.physbeh.2013.05.029. Epub 2013 May 29.

PMID:
23727535
9.

[Clinical stage and therapy].

Sagae S, Sugimura M, Nagata M.

Nihon Rinsho. 2012 Jun;70 Suppl 4:336-42. Japanese. No abstract available.

PMID:
23156267
10.

[Current movement in global clinical trials--discussion at Gynecologic Cancer Intergroup (GCIG)].

Sagae S, Aoki D, Susumu N, Okamoto A, Aotani E, Takeuchi M, Mandai M.

Nihon Rinsho. 2012 Jun;70 Suppl 4:59-66. Japanese. No abstract available.

PMID:
23156218
11.

Early onset of obesity induces reproductive deficits in female rats.

Sagae SC, Menezes EF, Bonfleur ML, Vanzela EC, Zacharias P, Lubaczeuski C, Franci CR, Sanvitto GL.

Physiol Behav. 2012 Mar 20;105(5):1104-11. doi: 10.1016/j.physbeh.2011.12.002. Epub 2011 Dec 11.

12.

Sex differences in brain cholinergic activity in MSG-obese rats submitted to exercise.

Sagae SC, Grassiolli S, Raineki C, Balbo SL, Marques da Silva AC.

Can J Physiol Pharmacol. 2011 Nov;89(11):845-53. doi: 10.1139/y11-082. Epub 2011 Nov 1.

PMID:
22039988
13.

[Proceeding of revision for neoplasm staging by FIGO].

Sagae S.

Gan To Kagaku Ryoho. 2011 Feb;38(2):203-6. Japanese. No abstract available.

PMID:
21452498
14.

Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG).

Rustin GJ, Vergote I, Eisenhauer E, Pujade-Lauraine E, Quinn M, Thigpen T, du Bois A, Kristensen G, Jakobsen A, Sagae S, Greven K, Parmar M, Friedlander M, Cervantes A, Vermorken J; Gynecological Cancer Intergroup.

Int J Gynecol Cancer. 2011 Feb;21(2):419-23. doi: 10.1097/IGC.0b013e3182070f17.

PMID:
21270624
15.

Less impact of adjuvant chemotherapy for stage I clear cell carcinoma of the ovary: a retrospective Japan Clear Cell Carcinoma Study.

Takano M, Sugiyama T, Yaegashi N, Sagae S, Kuzuya K, Udagawa Y, Tsuda H, Suzuki M, Kigawa J, Goto T, Tsuda H, Moriya T, Kikuchi Y.

Int J Gynecol Cancer. 2010 Dec;20(9):1506-10. doi: 10.1111/IGC.0b013e3181fcd089.

PMID:
21119366
16.

Evidence-based guidelines for treatment of uterine body neoplasm in Japan: Japan Society of Gynecologic Oncology (JSGO) 2009 edition.

Nagase S, Katabuchi H, Hiura M, Sakuragi N, Aoki Y, Kigawa J, Saito T, Hachisuga T, Ito K, Uno T, Katsumata N, Komiyama S, Susumu N, Emoto M, Kobayashi H, Metoki H, Konishi I, Ochiai K, Mikami M, Sugiyama T, Mukai M, Sagae S, Hoshiai H, Aoki D, Ohmichi M, Yoshikawa H, Iwasaka T, Udagawa Y, Yaegashi N; Japan Society of Gynecologic Oncology.

Int J Clin Oncol. 2010 Dec;15(6):531-42. doi: 10.1007/s10147-010-0138-6. Epub 2010 Nov 11.

PMID:
21069552
17.

Cervical Cancer Working Group report.

Konno R, Sagae S, Yoshikawa H, Basu PS, Hanley SJ, Tan JH, Shin HR.

Jpn J Clin Oncol. 2010 Sep;40 Suppl 1:i44-50. doi: 10.1093/jjco/hyq126.

PMID:
20870919
18.

The impact of complete surgical staging upon survival in early-stage ovarian clear cell carcinoma: a multi-institutional retrospective study.

Takano M, Sugiyama T, Yaegashi N, Suzuki M, Tsuda H, Sagae S, Udagawa Y, Kuzuya K, Kigawa J, Takeuchi S, Tsuda H, Moriya T, Kikuchi Y.

Int J Gynecol Cancer. 2009 Nov;19(8):1353-7. doi: 10.1111/IGC.0b013e3181a83f4f.

PMID:
20009889
19.

[Two cases of inoperable advanced bileduct cancer treated effectively with a gemcitabine/cisplatin combination].

Nakamura T, Kobayashi N, Saito J, Ikeda K, Okusawa S, Sagae S, Iwata K, Kurihara E.

Gan To Kagaku Ryoho. 2009 Nov;36(11):1893-6. Japanese.

PMID:
19920395
20.

Practice pattern for postoperative management of endometrial cancer in Japan: a survey of the Japanese Gynecologic Oncology Group.

Watanabe Y, Kitagawa R, Aoki D, Takeuchi S, Sagae S, Sakuragi N, Yaegashi N; Disease Committee of Uterine Endometrial Cancer, Japanese Gynecologic Oncology Group.

Gynecol Oncol. 2009 Dec;115(3):456-9. doi: 10.1016/j.ygyno.2009.08.016. Epub 2009 Sep 17.

PMID:
19765806
21.

Favourable prognosis with modified dosing of docetaxel and cisplatin in Japanese patients with ovarian cancer.

Aoki D, Watanabe Y, Jobo T, Ushijima K, Hasegawa K, Susumu N, Suzuki N, Aoki R, Isonishi S, Sagae S, Ishizuka B, Kamura T, Udagawa Y, Hoshiai H, Ohashi Y, Ochiai K, Noda K.

Anticancer Res. 2009 Feb;29(2):561-6.

22.

[Treatment for recurrent uterine cancer].

Sagae S, Sugimura M, Nagata M.

Gan To Kagaku Ryoho. 2009 Feb;36(2):220-3. Japanese. No abstract available.

PMID:
19263610
23.

[Chemotherapy of uterine cancer].

Sagae S, Sugimura M.

Gan To Kagaku Ryoho. 2008 Feb;35(2):218-223. Review. Japanese. No abstract available.

PMID:
18372510
24.

Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study.

Susumu N, Sagae S, Udagawa Y, Niwa K, Kuramoto H, Satoh S, Kudo R; Japanese Gynecologic Oncology Group.

Gynecol Oncol. 2008 Jan;108(1):226-33. Epub 2007 Nov 9.

PMID:
17996926
25.

Progression-free survival and overall survival of patients with clear cell carcinoma of the ovary treated with paclitaxel-carboplatin or irinotecan-cisplatin: retrospective analysis.

Takano M, Sugiyama T, Yaegashi N, Suzuki M, Tsuda H, Sagae S, Udagawa Y, Kuzuya K, Kigawa J, Takeuchi S, Tsuda H, Moriya T, Kikuchi Y.

Int J Clin Oncol. 2007 Aug;12(4):256-60. Epub 2007 Aug 20.

PMID:
17701003
26.

Status of surgical treatment procedures for endometrial cancer in Japan: results of a Japanese Gynecologic Oncology Group survey.

Watanabe Y, Aoki D, Kitagawa R, Takeuchi S, Sagae S, Sakuragi N, Yaegashi N; Disease Committee of Uterine Endometrial Cancer, Japanese Gynecologic Oncology Group.

Gynecol Oncol. 2007 May;105(2):325-8. Epub 2007 Jan 30.

PMID:
17267025
27.

Adjuvant chemotherapy with irinotecan hydrochloride and cisplatin for clear cell carcinoma of the ovary.

Takano M, Kikuchi Y, Yaegashi N, Suzuki M, Tsuda H, Sagae S, Udagawa Y, Kuzuya K, Kigawa J, Takeuchi S, Tsuda H, Moriya T, Sugiyama T.

Oncol Rep. 2006 Dec;16(6):1301-6.

PMID:
17089053
28.

Successful delivery after vaginal radical trachelectomy for invasive uterine cervical cancer.

Ishioka S, Endo T, Hayashi T, Kitajima Y, Sugimura M, Sagae S, Saito T.

Int J Clin Oncol. 2006 Apr;11(2):146-9.

PMID:
16622750
29.

Estradiol and progesterone modulation of angiotensin II receptors in the arcuate nucleus of ovariectomized and lactating rats.

Donadio MV, Gomes CM, Sagae SC, Franci CR, Anselmo-Franci JA, Lucion AB, Sanvitto GL.

Brain Res. 2006 Apr 14;1083(1):103-9. Epub 2006 Mar 29.

PMID:
16566904
30.

Epigenetic inactivation of TCF2 in ovarian cancer and various cancer cell lines.

Terasawa K, Toyota M, Sagae S, Ogi K, Suzuki H, Sonoda T, Akino K, Maruyama R, Nishikawa N, Imai K, Shinomura Y, Saito T, Tokino T.

Br J Cancer. 2006 Mar 27;94(6):914-21.

31.

Angiotensin II receptors are upregulated by estradiol and progesterone in the locus coeruleus, median preoptic nucleus and subfornical organ of ovariectomized rats.

Donadio MV, Gomes CM, Sagae SC, Franci CR, Anselmo-Franci JA, Lucion AB, Sanvitto GL.

Brain Res. 2005 Dec 14;1065(1-2):47-52. Epub 2005 Nov 17.

PMID:
16297888
32.

2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004).

du Bois A, Quinn M, Thigpen T, Vermorken J, Avall-Lundqvist E, Bookman M, Bowtell D, Brady M, Casado A, Cervantes A, Eisenhauer E, Friedlaender M, Fujiwara K, Grenman S, Guastalla JP, Harper P, Hogberg T, Kaye S, Kitchener H, Kristensen G, Mannel R, Meier W, Miller B, Neijt JP, Oza A, Ozols R, Parmar M, Pecorelli S, Pfisterer J, Poveda A, Provencher D, Pujade-Lauraine E, Randall M, Rochon J, Rustin G, Sagae S, Stehman F, Stuart G, Trimble E, Vasey P, Vergote I, Verheijen R, Wagner U; Gynecologic Cancer Intergroup; AGO-OVAR; ANZGOG; EORTC; GEICO; GINECO; GOG; JGOG; MRC/NCRI; NCIC-CTG; NCI-US; NSGO; RTOG; SGCTG; IGCS; Organizational team of the two prior International OCCC.

Ann Oncol. 2005;16 Suppl 8:viii7-viii12. No abstract available.

PMID:
16239238
33.

3rd International Ovarian Cancer Consensus Conference: outstanding issues for future consideration.

Stuart G, Avall-Lundqvist E, du Bois A, Bookman M, Bowtell D, Brady M, Casado A, Cervantes A, Eisenhauer E, Friedlaender M, Fujiwara K, Grenman S, Guastalla JP, Harper P, Hogberg T, Kaye S, Kitchener H, Kristensen G, Mannel R, Meier W, Miller B, Oza A, Ozols R, Parmar M, Pfisterer J, Poveda A, Provencher D, Pujade-Lauraine E, Quinn M, Randall M, Rochon J, Rustin G, Sagae S, Stehman F, Trimble E, Thigpen T, Vasey P, Vergote I, Verheijen R, Vermorken J, Wagner U; NCIC-CTG; NSGO; AGO-OVAR; GOG; ANZGOG; EORTC; GEICO; JGOG; GINECO; MRC/NCRI; SGCTG; RTOG; NCI-US.

Ann Oncol. 2005;16 Suppl 8:viii36-viii38. No abstract available.

PMID:
16239235
34.

Clinical trials in ovarian carcinoma: study methodology.

Vermorken JB, Parmar MK, Brady MF, Eisenhauer EA, Hogberg T, Ozols RF, Rochon J, Rustin GJ, Sagae S, Verheijen RH; Gynecologic Cancer Intergroup; EORTC; MRC/NCRI; GOG; NCIC-CTG; NSGO; AGO-OVAR; JGOG.

Ann Oncol. 2005;16 Suppl 8:viii20-viii29. No abstract available.

PMID:
16239233
35.

The reproducibility of a binary tumor grading system for uterine endometrial endometrioid carcinoma, compared with FIGO system and nuclear grading.

Sagae S, Saito T, Satoh M, Ikeda T, Kimura S, Mori M, Sato N, Kudo R.

Oncology. 2004;67(5-6):344-50.

PMID:
15713989
36.

[Prognostic factors in advanced ovarian cancer patients].

Terasawa K, Sagae S.

Nihon Rinsho. 2004 Oct;62 Suppl 10:592-6. Review. Japanese. No abstract available.

PMID:
15535314
37.

[Surgical treatment for ovarian cancer].

Kudo R, Ishioka S, Sagae S.

Nihon Rinsho. 2004 Oct;62 Suppl 10:522-6. Review. Japanese. No abstract available.

PMID:
15535300
38.

[Cancer prevention].

Mori M, Sagae S.

Nihon Rinsho. 2004 Oct;62 Suppl 10:17-21. Review. Japanese. No abstract available.

PMID:
15535199
39.

Preoperative diagnosis and treatment results in 106 patients with uterine sarcoma in Hokkaido, Japan.

Sagae S, Yamashita K, Ishioka S, Nishioka Y, Terasawa K, Mori M, Yamashiro K, Kanemoto T, Kudo R.

Oncology. 2004;67(1):33-9.

PMID:
15459493
40.

[A pilot study of combined chemotherapy with paclitaxel, doxorubicin and cisplatin for endometrial cancer].

Honma H, Sagae S, Terasawa K, Tanaka R, Chida M, Mizumoto H, Ishioka S, Saito T, Kudo R.

Gan To Kagaku Ryoho. 2004 Apr;31(4):549-53. Japanese.

PMID:
15114698
41.

Ultrastructural study of benign, low-malignant potential (LMP), and malignant ovarian tumors.

Ishioka S, Sagae S, Ito E, Kudo R.

Med Electron Microsc. 2004 Mar;37(1):37-44. Review.

PMID:
15057603
42.

Angiotensin II receptors in the arcuate nucleus mediate stress-induced reduction of prolactin secretion in steroid-primed ovariectomized and lactating rats.

Donadio MV, Sagae SC, Franci CR, Anselmo-Franci JA, Lucion AB, Sanvitto GL.

Brain Res. 2004 Apr 23;1006(1):59-65.

PMID:
15047024
43.

Epigenetic inactivation of TMS1/ASC in ovarian cancer.

Terasawa K, Sagae S, Toyota M, Tsukada K, Ogi K, Satoh A, Mita H, Imai K, Tokino T, Kudo R.

Clin Cancer Res. 2004 Mar 15;10(6):2000-6.

44.

Mechanisms of paclitaxel-induced apoptosis in an ovarian cancer cell line and its paclitaxel-resistant clone.

Sugimura M, Sagae S, Ishioka S, Nishioka Y, Tsukada K, Kudo R.

Oncology. 2004;66(1):53-61.

PMID:
15031599
45.

Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer).

Rustin GJ, Quinn M, Thigpen T, du Bois A, Pujade-Lauraine E, Jakobsen A, Eisenhauer E, Sagae S, Greven K, Vergote I, Cervantes A, Vermorken J.

J Natl Cancer Inst. 2004 Mar 17;96(6):487-8. No abstract available.

PMID:
15026475
46.

A relationship between Matrix metalloproteinase-1 (MMP-1) promoter polymorphism and cervical cancer progression.

Nishioka Y, Sagae S, Nishikawa A, Ishioka Si, Kudo R.

Cancer Lett. 2003 Oct 8;200(1):49-55.

PMID:
14550952
47.

Comparison of the usefulness between a new universal grading system for epithelial ovarian cancer and the FIGO grading system.

Ishioka Si, Sagae S, Terasawa K, Sugimura M, Nishioka Y, Tsukada K, Kudo R.

Gynecol Oncol. 2003 Jun;89(3):447-52.

PMID:
12798710
48.

Reproductive function after treatment of malignant germ cell ovarian tumors.

Sagae S, Sasaki H, Nishioka Y, Terasawa K, Kudo R.

Mol Cell Endocrinol. 2003 Apr 28;202(1-2):117-21.

PMID:
12770740
49.
50.

Proposal of a new scoring scheme for the diagnosis of noninvasive endocervical glandular lesions.

Ioffe OB, Sagae S, Moritani S, Dahmoush L, Chen TT, Silverberg SG.

Am J Surg Pathol. 2003 Apr;27(4):452-60.

PMID:
12657929

Supplemental Content

Support Center